Goldman Sachs
CRBP icon

Goldman Sachs’s Corbus Pharmaceuticals CRBP Stock Holding History

Goldman Sachs’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,000
Closed -$526K – 5182
2018
Q4 		$526K Buy
3,000
+1,667
+125% +$333K ﹤0.01% 4336
2018
Q3 		$302K Buy
+1,333
New +$216K ﹤0.01% 4711

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Goldman Sachs's CRBP Position: Q2 2026 in Review

Goldman Sachs reduced its Corbus Pharmaceuticals (CRBP) stake by 32% in Q2 2026, selling an estimated $286K and leaving 62,863 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #5596.

Goldman Sachs first reported a position in CRBP in Q4 2017 and has held it in 29 quarters since. The position peaked at $4.17M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Goldman Sachs held 62,863 shares of Corbus Pharmaceuticals worth $590K as of Q2 2026.
  • Goldman Sachs sold 30,248 Corbus Pharmaceuticals shares in Q2 2026, an estimated $286K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5596 holding.
  • Goldman Sachs first reported a position in Corbus Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
  • Goldman Sachs's Corbus Pharmaceuticals position peaked at $4.17M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.